American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and …
K Cusi, S Isaacs, D Barb, R Basu, S Caprio… - Endocrine Practice, 2022 - Elsevier
Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …
Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease
F Kanwal, JH Shubrook, LA Adams, K Pfotenhauer… - Gastroenterology, 2021 - Elsevier
Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.
gastro. org. Scan this QR code to be taken directly to the website. Nonalcoholic fatty liver …
gastro. org. Scan this QR code to be taken directly to the website. Nonalcoholic fatty liver …
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update
Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD
Hepatic steatosis is a key histological feature of nonalcoholic fatty liver disease (NAFLD).
The non-invasive quantification of liver fat is now possible due to advances in imaging …
The non-invasive quantification of liver fat is now possible due to advances in imaging …
Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening
R Lomonaco, E Godinez Leiva, F Bril… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver
fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 …
fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 …
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. In
some patients with NAFLD, isolated steatosis can progress to advanced stages with non …
some patients with NAFLD, isolated steatosis can progress to advanced stages with non …
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading
cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease …
cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease …
Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial
K Cusi, B Orsak, F Bril, R Lomonaco… - Annals of internal …, 2016 - acpjournals.org
Background: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes
or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone …
or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone …
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic …
Abstract Background and Aim: The magnitude of the risk of incident type 2 diabetes (T2D)
and metabolic syndrome (MetS) among patients with nonalcoholic fatty liver disease …
and metabolic syndrome (MetS) among patients with nonalcoholic fatty liver disease …